# Novocardia

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/novocardia

- Industry: Healthcare Specialists
- Headquarters: Waltham, US
- Website: www.novocardiahealth.com
- Total disclosed funding: $54M
- Latest round: Series A (Jun 28, 2021)
- Investors on record: 1

## About

Based in the US, Novocardia specializes in value-based care models tailored for cardiovascular health management, enhancing clinical efficiency and patient outcomes through timely and affordable care solutions.Founded in 2020 in Waltham, US, Novocardia focuses on innovative cardiovascular health strategies. The company was recently acquired by Cardiovascular Associates of America, enabling it to expand its reach across eight US states. The founder's details are currently unavailable. The company raised a total of USD 53.70 mn during its Series A funding round led by Deerfield Management, with the latest deal occurring on April 18, 2023.Novocardia offers a comprehensive value-based care model designed specifically for the management of cardiovascular health. Central to their offerings is the optimization of clinical efficiency through enhanced access to timely, high-quality, and affordable cardiovascular care. This model addresses the urgent need for improved patient outcomes by reducing avoidable hospitalizations and emergency room visits, particularly for patients with chronic cardiovascular diseases. Targeted primarily at primary care groups and payers, Novocardia collaborates with a wide client base, including Humana Medicare Advantage Plan members through its partnership with Cardiovascular Associates of America. The service extends across multiple states, ensuring that patients benefit from specialized services and enhanced care coordination. Their innovative approach employs proprietary technology and analytics to streamline care delivery and address patient needs in real time.Novocardia generates revenue through its partnerships and value-based care agreements, most notably with entities like Humana. The revenue model relies on collaborative arrangements where shared performance data drives improvements in care quality and cost efficiency. Transactions typically occur through partnerships with healthcare providers, focusing on outcomes-based reimbursement rather than traditional fee-for-service models. These collaborations allow Novocardia to deliver specialized cardiovascular care while managing chronic conditions, ultimately leading to cost savings for clients. While specific pricing structures for individual services or products are not disclosed, the focus on value-based care suggests a framework where financial success is aligned with patient outcomes, fostering long-term relationships with healthcare providers and payers in the market.Following its acquisition in April 2023, Novocardia plans to enhance its cardiovascular care models and broaden its services across eight US states. The recent funding will support the development and expansion of their offerings as they aim to reach more patients effectively. Specific new products are currently in the design phase, with targeted launches as the company scales its operational capacity.

## Funding rounds

- Series A, Jun 28, 2021, $54M — Deerfield Management

## Investors

- Deerfield Management (https://capitalatlas.ai/funds/deerfield-management) — Series A